Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05539729
PHASE1

Vancomycin Study in Multiple Sclerosis (MS)

Sponsor: Icahn School of Medicine at Mount Sinai

View on ClinicalTrials.gov

Summary

The overall goal of this study is to elucidate a mechanism by which vancomycin modulates the gut-brain axis in multiple sclerosis (MS). The gut microbiome plays an important role in autoimmunity, including MS. However, the identity of gut microbes modulating neuroinflammation in MS and their mechanisms of action remain obscure. Hence, here the research team proposes to investigate the effects of vancomycin on the gut microbiota composition, peripheral immune function, and brain MRI lesions in MS patients.

Official title: Impact of Vancomycin on the Gut Microbiome and Immune Function in Multiple Sclerosis

Key Details

Gender

All

Age Range

18 Years - 50 Years

Study Type

INTERVENTIONAL

Enrollment

12

Start Date

2023-01-31

Completion Date

2026-09

Last Updated

2025-09-10

Healthy Volunteers

No

Interventions

DRUG

Vancomycin

A marketed antibiotic (Study Drug) supplied by Amerisource Bergen, by the Mount Sinai Investigational Drug Services (IDS), and encapsulated in red coating to match the placebo.

DRUG

Placebo

Placebo created by the IDS and encapsulated in red coating to match the Study Drug.

Locations (1)

Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai

New York, New York, United States